An observational study in Covid-19, sponsored by Corporacion Parc Tauli. Completed at 1 site in Spain. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-29.
Sponsored by Corporacion Parc Tauli · Observational
Ycovid-19 aims to be a rapid diagnostic test for SARS-CoV-2 infection, which will allow a reliable diagnosis to be made in 10 minutes, and on easy-to-use devices. This test will be developed using innovative technology developed at the Parc Taulí University Hospital, which increases the immunogenicity of SARS-CoV-2 differential antigens. The increased immunogenicity of these antigens will allow to detect, with a high sensitivity and specificity, the antibodies in the serum of patients infected with SARS-CoV-2. This test will serve to confirm dubious results as well as reduce false negatives from the PCR test, which will ultimately help reduce transmission of the infection.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 3,500 is above the median of 261 across 3,136 observational studies indexed under COVID-19.
Browse COVID-19 studies →Corporacion Parc Tauli is the lead sponsor of 163 studies on the registry; 25 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with COVID-19 infection Professionals of an University Hospital
Exclusion Criteria:
Patients with clinical, radiological and/or PCR positive for COVID-19 infection
Diagnostic Test: ELISA and Rapid test to detect antibodies against COVID-19
Normal human serum from blood donnors before COVID-19 pandemia
Diagnostic Test: ELISA and Rapid test to detect antibodies against COVID-19
Patients with other positive virological serologies
Diagnostic Test: ELISA and Rapid test to detect antibodies against COVID-19
Ycovid-19 aims to be a rapid diagnostic test for SARS-CoV-2 infection, which will allow a reliable diagnosis to be made in 10 minutes, and on easy-to-use devices
IgG anti-COVID-19
IgG antibodies against COVID-19 RBD
Time frame: From May to July
IgM anti-COVID-19
IgM antibodies against COVID-19 RBD
Time frame: From May to July
IgA anti-COVID-19
IgA antibodies against COVID-19 RBD
Time frame: From May to July
Time of onset symptoms
Time frame: From May to July
COVID-19 PCR results
Qualitative result to clasify patients into PCR COVID-19 positive patients and PCR COVID-19 negative patients
Time frame: From May to July
Radiological studies
The presence or abcense of the typical image of the pneumonia caused by COVID-19
Time frame: From May to July
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Corporacion Parc Tauli